Kuros Bioscience Ltd. financial statements, including revenue, expenses, profit, and loss
The total revenue of CSBTF for the last semiannual is 24.58 M USD, and it's 71.11% higher compared to the previous semiannual. The net income of H2 23 is -10.30 M USD.